PATENT CLAIM ANALYSIS

Application Number: 15743895
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["514", "020800"]

Abstract:
Provided is a nanoparticle-vitreous body-based protein complex, and more particularly, to a composition for inhibiting angiogenesis which includes the complex as an active ingredient, and a composition for preventing or treating an angiogenesis-related disease or a retinal disease. When the nanoparticle-vitreous body-based protein complex according to the subject matter is locally injected into the vitreous body, the complex exhibits significantly excellent binding strength with a vascular endothelial growth factor and thus can inhibit angiogenesis, thus being easily used to prepare a therapeutic agent for preventing, alleviating, or treating retinal and choroidal angiogenesis-related diseases.

Claim (Index 14):
The method of treating a retinal disease, including administering a pharmaceutically effective amount of a pharmaceutical composition to an individual, wherein the pharmaceutical composition comprises a complex consisting of nanoparticles and a vitreous body-based protein surrounding surfaces of the nanoparticles, as an active ingredient.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.67213
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12678898', '10902959', '12219179', '14740194', '15038269']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7890599132199968
- 35 USC 102 Novelty (BERT): 0.536869731155213
- Combined Prediction Score: 0.7638408950135184
- Mean Citation Score: 351.130206
- Max Citation Score: 359.86285
- Similarity Product: 245.2316955718905

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test